Popular on Social Media Does Not Mean FDA-Approved

Interest in a treatment can grow much faster than the evidence behind it.

That gap is where Med Spa owners need to be most careful. This week's market news covers a proposed federal law, a fast-rising peptide trend, two newly approved fillers, and a major court ruling involving Google. Each one affects what you decide to advertise, and how you advertise it.

Here are four developments worth knowing about.

When a treatment is trending, the safest campaign is still the same: start with education, use only claims you can support, and send every clinical question to your provider.

1. A proposed federal law could change who controls a medical practice

According to the American Med Spa Association, the Stop Corporate Takeovers of Physicians Act of 2026 was introduced on September 16 and referred to committee. As described, it would generally require medical practices to be majority-owned and controlled by licensed health professionals. It would also restrict certain management services organization (MSO) control over staffing, scheduling, billing, compensation, and operations.

It is important to be clear about where this stands. It is only a proposal. It is not current law, and it may change or go nowhere.

In our view, owners should still pay attention. If the idea gains momentum, investor-owned and MSO-supported practices may look more closely at their vendor relationships and at who controls what. A healthy setup is easy to describe: the practice makes the clinical decisions, and marketing and technology partners support the practice rather than run it.

Points worth having in writing with any marketing or technology partner:

• Your practice controls clinical policies and treatment eligibility.
• Your practice approves every claim, offer, and price before it runs.
• Your practice sets the rules for when automated conversations pass to your staff.
• Your practice can review, change, or pause any message at any time.

Ask your attorney how any proposed legislation could apply to your ownership structure. This is general education, not legal advice.

2. Peptide demand is moving faster than the evidence

Reuters reported on September 15 that documented use of unapproved BPC-157 increased substantially between 2020 and 2026. The FDA has not yet decided whether to permit its compounding, and researchers quoted in the report said the available data cannot establish its safety or effectiveness. The report also noted that eight of the ten serious adverse-event reports recorded since 2021 occurred during 2026, while making clear that such reports do not prove causation.

Consumer curiosity makes for tempting content. But promoting unapproved products with benefit claims can create exposure for the practice and for anyone who markets on its behalf. It also builds on a theme from earlier this fall: verify a treatment before you advertise it.

Simple guardrails to consider:

• Leave unapproved peptide names and unverified outcome claims out of paid ads and automated follow-up.
• Before any campaign, ask whether a service is compounded, off-label, experimental, or awaiting FDA action.
• Choose educational content that explains what is known and what is not, and invites readers to talk with a provider.
• Review any wellness or peptide offer with qualified counsel and your medical director before it goes public.

3. Two newly approved fillers open a timely, natural-results conversation

According to AmSpa, the FDA approved Belotero Volume (+) for adult midface volume deficits and Belotero Intense (+) for adult lip augmentation. Commercial availability is expected on October 14 and December 1, respectively. Any durability or positioning claims from the manufacturer should be checked against the approved labeling before they appear in an ad.

These launches fit a broader shift toward facial balance, preserved movement, and natural-looking restoration. Practices planning to offer them have a few weeks to educate prospects before availability, rather than waiting until competitors start advertising.

Ideas for a careful pre-launch approach:

• A waitlist or interest list with provider education, FAQs, consultation requests, and launch notifications.
• Messaging about facial balance without looking overdone, kept in line with the approved labeling.
• A plain-language guide to treatment areas and candidate considerations, without calling any one filler universally "better."
• Provider approval of every claim before it is published.

Whether a person is a good candidate for any treatment is a clinical decision for a licensed provider.

4. Google's ad-tech ruling is important, but not a reason to change campaigns yet

Reuters reported that on September 16, a federal judge ordered changes intended to open parts of Google's publisher ad-tech ecosystem to competition and required a six-year compliance monitor. Google plans to appeal aspects of the case, and the final judgment is still being drafted.

In our view, the ruling could eventually affect publisher inventory, auction competition, and programmatic pricing. It does not currently change Google Search campaign settings or healthcare-ad policies.

What that means in practice:

• Do not restructure campaigns based on this ruling alone.
• Keep measuring Search separately from Display and programmatic placements.
• Be skeptical of any claim that this ruling will immediately lower your Med Spa's advertising costs.

The takeaway

Trends will keep coming. A repeatable approach keeps you steady when they do. For any new or trending treatment, build the campaign around six steps:

• Start with education, not hype.
• Use only approved, supportable claims.
• Offer a consultation waitlist or interest list.
• Respond quickly to every inquiry.
• Send clinical questions straight to your licensed staff.
• Track booked appointments, not just clicks.

That approach is timely, commercially useful, and a safer path than chasing demand for products whose status is still unsettled.

This article is general education, not legal or medical advice. Elite Med Spa Solutions is a growth partner, not a law firm. Talk with qualified healthcare counsel and your medical director before you decide what your practice may offer and how it may be advertised.

If you want to book more appointments with an automated AI system built around responsible, accountable follow-up, book a FREE, no obligation strategy call. Visit EliteMedSpaSolutions.com to get started.

Sources

• American Med Spa Association (AmSpa), summary of the Stop Corporate Takeovers of Physicians Act of 2026, introduced September 16, 2026.
• Reuters, September 15, 2026, report on documented use of unapproved BPC-157.
• American Med Spa Association (AmSpa), report on FDA approval of Belotero Volume (+) and Belotero Intense (+).
• Reuters, September 16, 2026, report on the federal ruling on Google's publisher ad-tech.

Details above are summarized from these publications. Please review the original reports for the most current information.